PROGNOSTIC FACTORS IN PATIENTS WITH RELAPSED OR REFRACTORY SYSTEMIC ANAPLASTIC LARGE T‐CELL LYMPHOMA (ALCL) RECEIVING BRENTUXIMAB VEDOTIN AND OUTCOME AFTER TREATMENT FAILURE.
Sign Up to like & getrecommendations! Published in 2017 at "Hematological Oncology"
DOI: 10.1002/hon.2438_112
Abstract: Introduction: Despite high overall 5‐year survival rates for childhood HL and sALCL, improved options are needed for patients (pts) who do not respond to, or relapse following, initial therapy. This phase 1/ 2 open‐label, dose‐escalation… read more here.
Keywords: salcl pts; pts treated; treatment; brentuximab vedotin ... See more keywords